Clinical Trials Actively Recruiting Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Myeloma


Get Permission

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma. The trials are investigating combination treatments; modified chemotherapy regimens; autologous hematopoietic cell transplantations; and pediatric-specific cancers. All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov.

 

Pilot

Study Type: Pilot/interventional/single-group assignment

Study Title: Pilot Study of Rituximab and Brentuximab Vedotin With Deferred BMT for Relapsed Classical Hodgkin Lymphoma

Study Sponsor and Collaborators: Sidney Kimmel Comprehensive Cancer Center

Purpose: To study a combination of brentuximab vedotin and rituximab for the treatment of relapsed Hodgkin lymphoma

Primary Outcome Measures: 1-year failure free survival [time frame: 1 year]

Principal Investigator: Richard Jones, MD, The Johns Hopkins University; 443-287-7104, rjjones@jhmi.edu

For More Information: Use ClinicalTrials.gov Identifier NCT01900496


 

Phase I

Study Type: Phase I/interventional/single-group assignment

Study Title: Phase I Study of ­Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Mature T-Cell Non-Hodgkin Lymphoma: The aTAC BEAM ­Regimen

Study Sponsor and Collaborators: City of Hope Medical Center, National Cancer Institute

Purpose: To study the side effects and best dose of yttrium Y 90 basiliximab when given together with standard combination chemotherapy before a stem cell transplant in treating patients with mature T-cell non-Hodgkin lymphoma

Primary Outcome Measures: MTD of yttrium Y 90 basiliximab defined as the highest dose in which fewer than 33% of patients experience dose-limiting toxicity attributable to study treatment, among those evaluable for toxicity [time frame: 30 days post-transplant], Incidence of toxicities assessed using National Cancer Institute (NCI) CTCAE version 4.03 [time frame: Up to 100 days post-transplant]

Principal Investigator: Jasmine Zain, MD, City of Hope Medical Center; 800-826-4673, jzain@coh.org

For More Information: Use ClinicalTrials.gov Identifier NCT02342782


 

Phase I/II

Study Type: Phase I/II/interventional/single-group assignment

Study Title: A Phase I/II Study of Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma

Study Sponsor and Collaborators: Ohio State University Comprehensive Cancer Center

Purpose: To study the side effects and best dose of bendamustine hydrochloride when given together with gemcitabine hydrochloride and to see how well it works in treating patients with relapsed or refractory Hodgkin lymphoma

Primary Outcome Measures: Adverse events in terms of dose-limiting toxicity (DLT) and MTD of bendamustine hydrochloride (phase I) [time frame: up to 5 years]

Principal Investigator: Kristie Blum, MD, Ohio State University Comprehensive Cancer Center; 614-293-4590, kristie.blum@osumc.edu

For More Information: Use ClinicalTrials.gov Identifier NCT01535924


 

Phase II

Study Type: Phase II/Interventional/Parallel Assignment

Study Title: Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

Study Sponsor and Collaborators: National Heart, Lung, and Blood Institute; Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute

Purpose: To compare progression-free survival from randomization among patients randomized on the BMT CTN 1302 protocol, “Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Multiple Myeloma.” It is hypothesized that ixazomib maintenance therapy will result in improved progression-free survival in patients with high-risk multiple myeloma following allogeneic hematopoietic stem cell transplantation.

Primary Outcome Measures: Progression-free survival [time frame: 2 years postrandomization]

Principal Investigator: Mary Horowitz, MD, Center for International Blood and Marrow Transplant Research; contact Heather Wittsack, hwittsack@emmes.com.

For More Information: Use ClinicalTrials.gov Identifier NCT02440464


 

Phase III

Study Type: Phase III/interventional/parallel assignment

Study Title: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Study Sponsor and Collaborators: National Cancer Institute

Purpose: To study brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating younger patients with newly diagnosed Hodgkin lymphoma

Primary Outcome Measures: Event-free survival, where events include disease progression or relapse, second malignancy, or death [time frame: up to 48 months]

Principal Investigator: Sharon Castellino, MD, Children’s Oncology Group; multiple study locations, see clinicaltrials.gov for respective contact information.

For More Information: Use ClinicalTrials.gov Identifier NCT02166463


 

 

Study Type: Phase III/interventional/parallel assignment

Study Title: Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma

Study Sponsor and Collaborators: Hackensack University Medical Center

Purpose: To evaluate the use of melphalan in bone marrow transplant recipients

Primary Outcome Measures: To determine the progression-free survival of patients with multiple myeloma treated with tandem cycles of high-dose melphalan followed by high-dose melphalan in combination with bortezomib with autologous hematopoietic stem cell transplantation [time frame: 3 years]

Principal Investigator: Michele Donato, MD, John Theurer Cancer Center at Hackensack University Medical Center; mdonato@humed.com.

For More Information: Use ClinicalTrials.gov Identifier NCT01241708

Editor’s Note: The clinical trials presented here do not represent all the trials listed on ClinicalTrials.gov. For the complete list, go to ClinicalTrials.gov.

 



Advertisement

Advertisement



Advertisement